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A vaginal microbicide should prevent pathogen
transmission without disrupting tissue barriers to
infection. Ideally, it would not need to be applied
immediately before sexual intercourse, when compli-
ance is a problem. Intravaginal administration of
small interfering RNA (siRNA) lipoplexes targeting
Herpes Simplex Virus Type 2 (HSV-2) genes protects
mice from HSV-2. However, protection is short-lived,
and the transfection lipid on its own unacceptably
enhances transmission. Here, we show that choles-
terol-conjugated (chol)-siRNAs without lipid silence
gene expression in the vagina without causing
inflammation or inducing interferons. A viral siRNA
prevents transmission within a day of challenge,
whereas an siRNA targeting the HSV-2 receptor
nectin-1 protects for a week, but protection is
delayed for a few days until the receptor is downmo-
dulated. Combining siRNAs targeting a viral and host
gene protects mice from HSV-2 for a week, irrespec-
tive of the time of challenge. Therefore, intravaginal
siRNAs could provide sustained protection against
viral transmission.
INTRODUCTION
Genital Herpes Simplex Virus 2 (HSV-2) infection causes signifi-
cant morbidity (Whitley, 2001) and is an important cofactor for
HIV-1 infection (Wald and Link, 2002; Serwadda et al., 2003;
Corey et al., 2004). A vaginal microbicide able to protect against
HSV-2 transmission could contribute significantly to controlling
sexually transmitted diseases. Intravaginal (ivag) administration
of small interfering RNAs (siRNA) targeting two HSV-2 genes
(UL27 and UL29), when mixed with the transfection lipid
Oligofectamine (OF), protected mice against ivag challenge
with 2LD50 of HSV-2 (Palliser et al., 2006). Topical administration
was well tolerated, with no signs of inflammation or induction of
interferon response genes. siRNAswere effective when adminis-
tered around the time of viral challenge or within a few hours after
exposure. Effective siRNA delivery to the cervicovaginal and anal84 Cell Host & Microbe 5, 84–94, January 22, 2009 ª2009 Elsevier Inepithelium using lipoplexed siRNAs was also shown by
Ramratnam and colleagues (Zhang et al., 2006).
One of the major obstacles to developing an effective topical
agent is compliance, since most topical agents being consid-
ered need to be applied just before sexual intercourse. We
previously found that gene silencing is sustained for several
weeks in vivo in slowly dividing cells, including the genital tract
of progesterone-treated mice. This suggested that an siRNA-
based vaginal microbicide might be able to create a sustained
antiviral milieu in the genital tract that could circumvent the
need for application around the time of exposure. However,
when we lengthened the time between viral challenge
and siRNA application, mice treated with lipoplexed viral
siRNAs against HSV-2 were no longer protected. This promp-
ted us to explore ways of improving and prolonging the antiviral
effect.
In this study, we looked more closely at the durability of
protection and drug features of lipoplexed anti-herpes siRNAs.
We found several undesirable features: the transfection lipid,
on its own, enhanced viral infection, limiting the maximal
effective drug dose, and protection did not last for more than
a day. To bypass these problems, we investigated topical
administration of stabilized, cholesterol-conjugated siRNAs
(chol-siRNAs). Intravenously administered chol-siRNAs are
taken up by liver and jejeunal cells and silence apolipoprotein
B gene expression to reduce cholesterol levels in mice and
monkeys (Soutschek et al., 2004; Zimmermann et al., 2006).
However, the dose required for efficient silencing after systemic
administration (50 mg/kg) is generally considered too high to
be therapeutically useful. Nonetheless, for topical administra-
tion, dosing might not be a problem. Here, we find that chol-
siRNAs, stabilized with phosphorothioate (PS) residues at their
ends, silence gene expression in cervicovaginal epithelium in
the absence of a transfection reagent, without triggering
interferon or inflammatory response genes.
In a previous in vitro study, we found that siRNAs silencing the
HIV coreceptor CCR5 persisted for longer in nondividing HIV-
uninfectedmacrophages than siRNAs targeting HIV gag, leading
us to speculate that the expression of a target mRNA might lead
to a longer siRNA intracellular half-life (Song et al., 2003). The
cell-surface receptor nectin-1 has been identified as a receptor
for HSV-2 by binding to the viral envelope glycoprotein D (Krum-
menacher et al., 1998; Shukla et al., 2000). Nectin-1 is expressedc.
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is expressed throughout the menstrual cycle on human
epithelium, its expression on murine epithelium is restricted to
proestrus and diestrus, which correlates with susceptibility to
HSV-2 infection (Shukla et al., 2000; Linehan et al., 2004). During
diestrus, nectin-1 is predominantly located at the luminal edge of
the epithelial cells. Nectin-1 gene-targeted knockout mice are
less susceptible to HSV-2 infection, whereas no difference
in infectivity is observed in mice deficient for an alternative
HSV-2-entry receptor, HVEM (Taylor et al., 2007). Furthermore,
siRNA-mediated knockdown of nectin-1 expressed on the apical
surface of human epithelial cell lines results in reduced HSV-2
infection (Galen et al., 2006). We therefore investigated whether
knocking down nectin-1might interfere with HSV-2 infection and
provide more durable protection. Nectin-1 siRNAs inhibit HSV-2
infection in vitro and in vivo. Moreover, siRNAs against nectin-1
persist and durably silence nectin-1 gene expression for a week.
While mice treated with a UL29 siRNA are protected from viral
challenge only around the time of siRNA instillation, mice treated
with siRNAs against nectin-1 are protected for a week beginning
2 days after siRNA treatment, the time required to downmodu-
late the receptor. By combining UL29 and nectin-1 siRNAs,
administered at a total dose of 1 mg/kg on 2 consecutive days,
mice were uniformly protected for a week, irrespective of when
they were challenged.
RESULTS
Intravaginal Application of Oligofectamine Enhances
HSV-2 Transmission
When we tried to prolong protection from HSV-2 challenge in
mice treated with UL27 and UL29 siRNA by increasing the
dose of OF-complexed siRNA, there was no survival advan-
tage; instead, paradoxically, we observed increased lethality
(data not shown). OF-complexed siRNAs did not disrupt the
epithelium or cause detectable tissue cell death (Palliser
et al., 2006 and data not shown). Nonetheless, we wondered
whether increased concentrations of OF might enhance HSV-
2 uptake across the epithelium, possibly by increasing the
fusion of the viral envelope to cell membranes or mediating
an inflammatory response. Therefore, we examined the effect
of OF on its own on survival of mice challenged with HSV-2.
Mice were treated with 4 ml OF 2 hr prior and 4 hr after vaginal
HSV-2 administration, a dosing schedule similar to that which
conferred protection in Palliser et al., 2006. At each dose of
HSV-2 tested, mice treated with OF succumbed to infection
faster than control mice, and more mice died (comparison
between treated and untreated mice by stratified log-rank
test, p = 0.04; Figure 1A). Although 20% and 60% of mock-
treated mice survived when challenged with 2 LD50 and 1
LD50 virus, respectively, no OF-treatedmice survived. Similarly,
OF reduced survival of mice challenged with 0.5 LD50 from 60%
to 20%. Therefore, OF treatment reduced the LD50 approxi-
mately 4-fold. Immunofluorescent staining of vaginal tissue
sections isolated 24 hr following administration of two doses
of OF, 6 hr apart, showed a slight but significant (p < 0.05)
increase in CD45+ cells in the lamina propria (Figure 1B [top
panel]). Hematoxylin and eosin staining of vaginal tissue iso-
lated at the same time showed no other signs of inflammationCellor tissue disruption (Figure 1B [bottom panel]). These results
suggest that OF causes some inflammation that might enhance
viral transmission.
Naked siRNAs Have a Short Half-Life in Vaginal Fluid
We therefore decided to investigate lipid-independent siRNA
delivery. Our previous study was performed using chemically
unmodified siRNAs. However, we were concerned that although
complexation into lipoplexesmight protect siRNAs from ambient
RNases, unmodified uncomplexed siRNAs might be rapidly
degraded in the genital tract. To evaluate the stability of uncom-
plexed and unmodified siRNA in cervicovaginal washes, we
analyzed their stability by RNA gel electrophoresis after incuba-
tion in mouse genital wash fluid. Within 15 min of incubation at
37C, no signal was detectable (Figure 1C). However, siRNAs
modified by a single PS substitution at each 30-end were still
detected after 3 hr incubation (Choung et al., 2006). Therefore,
RNases in cervicovaginal secretions could potentially interfere
with effective silencing; all subsequent experiments were thus
performed using PS-modified siRNAs.
Knocking Down Nectin-1 Reduces HSV-2 Infection
In Vitro
In the murine genital mucosa, susceptibility to HSV-2 infection
varies with the estrus cycle and is maximal at diestrus (Parr
et al., 1994). As previously reported (Linehan et al., 2004),
susceptibility coincides with nectin-1 expression: at diestrus,
the epithelial layer is maximally thin, and nectin-1 is highly ex-
pressed on the luminal side of the epithelium; while in proestrus,
the epithelial layer is thickened, and nectin-1 is only expressed
dimly near the basement membrane (Figure 2A). We therefore
used the Dharmacon design program to design two nectin-1
siRNAs, which targeted the nectin sequence beginning at nt
742 (siRNA #1) and nt 1234 (siRNA #2), to investigate whether
knocking down nectin-1 inhibits HSV-2 infection. Both siRNAs
knocked down nectin-1 and inhibited HSV-2 infection, but
siRNA #1 provided better knockdown and antiviral effect
(Figures 2B and 2C and data not shown). Phosphorothioated
(PS-) siRNA #1 was more effective than unmodified siRNA #1,
even in vitro (Figure 2C; p < 0.05). Therefore, PS-siRNA #1 was
used for all subsequent experiments.
More Durable Inhibition of HSV-2 Replication
In Vitro by Silencing Nectin-1 Than by Silencing UL29
Our next goal was to determine whether silencing nectin-1 might
have a more durable antiviral effect than silencing the viral DNA-
binding protein UL29. NIH 3T3 cells transfected on 2 consecutive
days with siRNAs targeting either nectin-1 orUL29were infected
with HSV-2 2, 4, or 7 days later. Viral replication, assessed by
plaque assay, was significantly reduced by the nectin-1 siRNA,
30-fold at each time point (Figure 3A; p < 0.001). UL29 siRNA
reduced viral replication 53-fold when NIH 3T3 cells were
infected with HSV-2 2 days after transfection (p < 0.001) and
3-fold after 4 days (p < 0.05), but there was no protection
when the challenge was deferred for 7 days. Therefore, the
nectin-1 siRNA had a sustained antiviral effect, while protection
afforded by the UL-29 siRNA was short-lived. To evaluate
whether the difference in durability might be due to a difference
in siRNA half-life, we used northern blot to quantify nectin-1 andHost & Microbe 5, 84–94, January 22, 2009 ª2009 Elsevier Inc. 85
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An siRNA-Based HSV-2 MicrobicideFigure 1. Oligofectamine Enhances HSV-2 Transmission
(A) Mice given Oligofectamine (OF, dashed lines) ivag 2 hr before and 4 hr after challenge with different doses of HSV-2 were more susceptible to viral infection
than control mice treated with PBS (solid lines).
(B) Increase in CD45+ cells in vaginal lamina propria of mice given OF twice, 6 hr apart. Twenty-four hours after OF treatment, frozen sections of vaginal tissue
were stained with antibody to CD45 or isotype control (red) and DAPI (blue) (top). Representative images (left) and mean ± SD (right) of the ratio of CD45+ cells/
total DAPI+ cells in the lamina propria in ten fields of vision are shown (*, p < 0.05). Hematoxylin and eosin staining of paraffin-embedded vaginal sections,
harvested 24 hr following OF treatment (bottom), shows no gross signs of inflammation (103 magnification).
(C) When not complexed with a transfection lipid, unmodified siRNAs were rapidly degraded in vaginal wash fluid at 37C compared to PS-modified siRNAs (PS).
Arrow indicates siRNA.UL29 siRNAs in NIH 3T3 cells (Figures 3B and 3C). Both siRNAs
declined with similar half-lives (1.9 days for nectin-1 siRNA and
1.4 days for UL29 siRNA, p > 0.05), although the nectin-1 siRNA
signal on the blots was significantly more intense (2.5-fold on day
1). Both probes have calculated melting temperatures that differ
by less than a degree (nectin-1 siRNA probe Tm = 52.1
C; UL29
siRNA Tm = 51.2
C; hybridization T = 42C), suggesting that the
difference in siRNA signal was not due to a difference in hybrid-
ization efficiency, but rather reflected a real difference in the
intracellular level of nectin-1 siRNA compared to the UL29
siRNA. It is likely that maintaining higher intracellular levels of
nectin-1 siRNA results in a more prolonged antiviral effect.86 Cell Host & Microbe 5, 84–94, January 22, 2009 ª2009 ElsevierDurable Nectin-1 Silencing by Chol-siRNA In Vivo
Since transfected nectin-1 siRNAs provided protection against
HSV-2 replication in vitro for at least a week, even in dividing
NIH 3T3 cells, we next wanted to know whether we could
achieve durable silencing in vivo. In an initial experiment, we
instilled 1 mg/kg lipoplexed siRNAs twice ivag into medroxypro-
gesterone-pretreated mice. Nectin-1 protein expression, evalu-
ated by fluorescence microscopy, was almost fully extinguished
by day 1, was not detected on day 2, and remained undetectable
on day 7 (Figure 4A). Nectin-1 mRNA quantified by qRT-PCR
was significantly decreased at all times evaluated (Figure 4B).
Our next goal was to determine if we could obtain silencingInc.
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that Is Upregulated in the Vagina During Diestrus When Mice Are
Susceptible to HSV-2, Reduces HSV-2 Replication In Vitro
(A) Nectin-1 (red) expression is enhanced at the luminal epithelial surface at
diestrus (left) compared to proestrus (right). Nuclei are stained with DAPI
(blue). The epithelial luminal surface is indicated with a white arrow, and the
basement membrane with a yellow arrow (310). The epithelium is thinned
during diestrus.
(B) Nectin-specific siRNAs #1 and #2 both downmodulate nectin-1 mRNA
expression, which was assessed relative to Gapdh 24 hr after transfection
by qRT-PCR in NIH 3T3 cells. Transfection with a control siRNA targeting
the SET protein had no effect on nectin-1 mRNA expression.
(C) Knocking down nectin-1 inhibits HSV-2 replication in NIH 3T3 cells. Cells
were transfected on 2 consecutive days with either unmodified or PS-modified
siRNA complexed with OF and then infected with HSV-2 the next day and har-
vested 20 hr later. Data show mean viral titer ± SD **, p < 0.001. PS-siRNAsCelwithout using a transfection lipid. siRNAs have been reported to
be taken upby pulmonary epithelial cells evenwithout a transfec-
tion lipid (Bitko et al., 2005). However, when mice were treated
on 2 consecutive days with either unmodified or PS-modified
nectin-1 siRNAs (1 mg/kg) in the absence of OF, nectin-1 protein
was not reduced when analyzed 1 day following the last dose, at
a time that nectin-1 expression is decreased using OF-com-
plexed siRNAs (Figure 4C). In the same experiment, we also eval-
uated knockdown using the same dose of nectin-1 chol-siRNA
without transfection lipid, which knocked down nectin-1 very
effectively. We therefore investigated whether chol-siRNAs
might efficiently and durably silence nectin-1 in the genital tract
without requiring a transfection lipid (Figures 4D and 4E). Mice
treated with either no siRNAs or chol-siRNAs targeting an irrele-
vant protein (GFP) expressed equivalent levels of nectin-1. Treat-
ment with nectin-1 chol-siRNA (1 mg/kg 3 2) downmodulated
nectin-1 expression for at least 12 days. Although immunofluo-
rescent staining for nectin-1 began to be detected on day 12 (still
at reduced levels compared to control mice), nectin-1 mRNA
expression remained low. Therefore, chol-siRNA without OF
can silence nectin-1 efficiently and durably in the genital tract.
A Combination of Nectin-1 and UL29 Chol-siRNAs
Protects Mice for 1 Week
To test the effectiveness of nectin-1 chol-siRNAs at protecting
against HSV-2 transmission, we first did a pilot experiment to
define the dose response of chol-siRNAs using chol-conjugated
UL29 siRNA without OF and a dosing schedule that provided
protection in the earlier study (Palliser et al., 2006). Mice were
treated ivag with UL29 chol-siRNA or mock-treated 2 hr prior
and 4 hr following HSV-2 challenge with 2 LD50 of virus (Fig-
ure 5A). Twenty percent of control mice (1 of 5) survived this viral
challenge. There was no increased survival in mice that received
0.25mg/kgUL29 chol-siRNA, but 3 of 5mice (60%) that received
injections of 0.5 mg/kg UL29 chol-siRNA (1 nmol, twice the dose
used in Palliser et al., 2006) survived, and 80% of mice given 1 or
2 mg/kg survived. However, a higher dose (5 mg/kg) did not
provide protection for unclear reasons. We chose 1 mg/kg
(2 nmol), the lowest dose that provided optimal protection, for
subsequent challenge experiments.
To investigate the onset and duration of protection, mice were
treated at various times with nectin-1 and/or UL29 chol-siRNAs,
given either before or after HSV-2 infection, and were followed
for 14 days for clinical signs of disease, using a well-established
scoring system, and survival. Twenty percent of mice that did not
receive siRNAs or receivedGFP chol-siRNAs survived the 2 LD50
HSV-2 challenge (Figures 5B and 5C). As previously shown with
lipoplexed siRNAs (Palliser et al., 2006), mice that received UL29
chol-siRNAs either around the time of challenge or shortly there-
after were protected (Figure 5D). However, mice treated with
UL29-1 chol-siRNAs 1 and 2 days before viral challenge or
before then were not significantly protected (log-rank test for
survival comparing pre- and postinfection treatment groups,
p < 0.01). Administering nectin-1 chol-siRNA 1 and 2 days or 3
and 4 days prior to HSV-2 challenge protected 60% of mice,
afforded significantly more protection than unmodified siRNAs (p < 0.05).
Values above bars show fold reduction in viral plaques. Data are representa-
tive of at least two experiments.l Host & Microbe 5, 84–94, January 22, 2009 ª2009 Elsevier Inc. 87
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An siRNA-Based HSV-2 MicrobicideFigure 3. Nectin-1 siRNAs Provide More Lasting Protection against HSV-2 Than UL29 siRNAs In Vitro
(A) NIH 3T3 cells were transfected on 2 consecutive days with nectin-1 (black), UL29 (dark gray), or GFP (light gray) siRNA or mock-transfected (white), then
challenged with HSV-2 either 2, 4, or 7 days later. Viral titers assessed the following day by plaque assay show more prolonged protection from knocking
down nectin-1 than with the antiviral siRNA. Values above bars show fold reduction in viral plaques. Data show mean ± SD *, p < 0.05; **, p < 0.001, compared
with control.
(B and C)Nectin-1 andUL29 siRNA antisense strands were assessed at indicated days after transfection by northern blot and quantified by densitometry relative
to U6 RNA. Although the siRNA half-lives were similar, more nectin-1 than UL29 siRNA was present at all times. In (C), the relative expression of each siRNA was
normalized to its value on day 1.while 80% of mice were protected when siRNAs were given
7 days before challenge. However, there was no benefit to
mice injected with nectin-1 chol-siRNA immediately before or
after HSV-2 (survival by log-rank test, p = 0.007, comparing
pre- and post-challenge groups). Combining nectin and UL29
chol-siRNAs gave uniform and significant protection irrespective
of the time of challenge (60%–80% survival, p = 0.007, log-rank
test compared with the control). The disease course was consis-
tent with histological examination of cervicovaginal tissue stained
with hematoxylin and eosin isolated 6 days after viral challenge of
mice given 1 mg/kg chol-siRNAs 1 and 2 days prior to the chal-
lenge. The vaginal tissue of mice that were mock-treated or given
GFP chol-siRNA showed swelling, epithelial erosion, intense
inflammatory infiltrates, and apoptosis (Figure 5E). By contrast,
tissues fromchallengedmice that received chol-siRNAs targeting
nectin-1 and UL29 were virtually normal.
Nectin and UL29 Chol-siRNAs Do Not Activate
Inflammation or Interferons
As siRNA treatment can induce interferon and inflammatory
responses that might have a nonspecific antiviral effect or alter
normal tissue homeostasis (Schlee et al., 2006), we analyzed88 Cell Host & Microbe 5, 84–94, January 22, 2009 ª2009 Elsevier Invaginal tissue from mice given chol-siRNA for inflammation
and cytokine expression. Vaginas were harvested 1 day after
mice were either mock-treated or given siRNAs that targeted
GFP, nectin-1, UL29, or a mixture of nectin-1 and UL29 on 2
consecutive days. No inflammation was observed in hematoxylin
and eosin-stained tissue sections (Figure 6A). In comparison,
cellular infiltrates were present in vaginal sections from a mouse
infected with 50 LD50 HSV-2 for 24 hr as a positive control (Fig-
ure 6A). mRNAs for interferon and interferon-regulated genes
Ifnb, Stat1, and Oas1, assessed by qRT-PCR on samples har-
vested 24 hr after the second dose, were also not upregulated
in mice given any of these siRNAs (Figure 6B). Vaginal tissue
from mice treated with 1 mg/kg chol-siRNA targeting GFP or
nectin-1 on 2 consecutive days was also analyzed for induction
of IL12 and IfngmRNAs 24 hr after the second instillation by qRT-
PCR and compared with untreated mouse vaginal tissue
(Figure 6C). These genes also were not significantly induced.
DISCUSSION
Topical administration of chol-siRNAs targeting an HSV-2 viral
gene and a host receptor induced sustained viral resistance inc.
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challengewith 2 LD50 of HSV-2 for at least aweek, independently
of whether the challenge was performed just before siRNA
administration or delayed until a week later. The administered
siRNAs were stabilized by a single PS linkage to protect them
from degradation by genital fluid RNases and were cholesterol
conjugated to facilitate intracellular entry.
These results improve upon our earlier study that used lipo-
plexed unmodified antiviral siRNAs (Palliser et al., 2006). We
found that we needed to modify the approach we had developed
Figure 4. Chol-siRNAs Downmodulate Nectin-1 Expression for a Week In Vivo without Requiring a Transfection Lipid
(A and B) Nectin-1 siRNAs (1 mg/kg) complexed with OF administered ivag for 2 consecutive days downregulate nectin-1 within a day of the second instillation,
and downregulation persists for at least 7 days. (A) shows immunofluorescence microscopy images of sections stained with nectin-1 or isotype control antibody
(red) and DAPI (blue), while (B) and (E) provide quantification of nectin mRNA relative to Gapdh by qRT-PCR (OF only [black], GFP siRNA [dark gray], nectin-1
siRNA [light gray]). Controls were harvested 1 day after the second transfection.
(C) Nectin-1 siRNAs (1 mg/kg3 2) administered ivag without a transfection reagent do not knock down nectin-1 expression, but the same dose of chol-siRNAs
does. Vaginal sections were harvested 2 days after the second treatment and stained for nectin-1 and DAPI as above.
(D and E)Nectin-1 knockdown by chol-siRNAs is sustained for over aweek. Data for (B) and (E) aremean ± SD *, p < 0.05, **, p < 0.001. Control animals were given
OF only (black) or GFP siRNA (dark gray). Images are magnified 310. Data shown are representative of two experiments.
Cell Host & Microbe 5, 84–94, January 22, 2009 ª2009 Elsevier Inc. 89
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An siRNA-Based HSV-2 MicrobicideFigure 5. Chol-siRNAs Targeting Nectin-1 and UL29 Confer Durable Protection from Lethal HSV-2 Infection for a Week
(A) Dose response for protection from challenge with 2 LD50 HSV-2 by UL29 chol-siRNA. Groups of five mice were given the indicated dose of UL29 chol-siRNA
2 hr prior and 4 hr following viral challenge. Optimal protection was achieved with 1 and 2.5 mg/kg.
(B–D) Groups of five mice received no siRNA (B),GFP chol-siRNA (administered 2 hr before and 4 hr after viral challenge) (C), or nectin-1 and/orUL29 chol-siRNA
(D) at indicated times. The total siRNA dose for each administration was 1 mg/kg. Mice were scored for disease severity (purple, no signs of disease; blue, slight
genital erythema and edema; green, moderate genital inflammation; yellow, purulent genital lesions; orange, hind limb paralysis; 5, death) over 14 days. TheUL29
chol-siRNA protected around the time of viral challenge while the nectin-1 siRNA did not become effective until a few days later, but protection persisted for
a week. Combining both siRNAs provided protection from challenge at any time during the week.
(E) Vaginal histopathology (hematoxylin and eosin staining) 6 days following infection inmice treated as indicated. (Boxes indicatemagnified area below.) Data are
representative of two experiments. Mice treated with a combination of nectin-1 and UL29 chol-siRNAs had essentially no signs of inflammation or cell death.for a topical siRNA-based antiviral microbicide, because the
transfection lipid used to deliver the siRNAs into cells on its
own facilitated viral infection, and because protection was
short-lived. Our results suggest that the lipid transfection
reagent induced slight but significant inflammation as measured90 Cell Host & Microbe 5, 84–94, January 22, 2009 ª2009 Elsevierby an increase in infiltrating hematopoietic cells, and this may be
sufficient to enhance viral uptake, resulting in a decrease in
mouse survival. Alternatively, the transfection lipid might
enhance viral entry by facilitating fusion of the viral envelope
with the cell membrane. Therefore, lipoplexed siRNAs shouldInc.
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An siRNA-Based HSV-2 MicrobicideFigure 6. Chol-siRNAs Do Not Cause Inflammation or Activate Interferon-Response Genes
(A and B) Vaginal tissue was harvested from mice 1 day following the second of two treatments with 2 nmol chol-siRNA (no HSV-2; bottom panel). Control mice
(top panel) were treated with either PBS alone (mock) or with HSV-2 without any siRNA (HSV-2). Vaginal tissue was divided into two for analysis by hematoxylin
and eosin staining (A) (310magnification) or for RNA extraction for qRT-PCR analysis of interferon-responsive genes Ifnb (black),Stat1 (gray) andOas1 (white) (B).
The chol-siRNAs did not induce inflammation or interferon-responsive gene expression.
(C) RNA was also extracted from vaginal tissue of mice treated with 2 nmol chol-siRNA twice (without OF) 1 day following the second treatment and analyzed
by qRT-PCR for Ifng (left) and IL12 (right). Positive controls (+, black) were anti-CD3-/CD28-activated T cells (Ifng) and LPS-activated splenocytes (IL12).
PBS-treated vaginal tissues served as negative control samples (, white). siRNAs targeted either GFP (dark gray) or nectin-1 (light gray). Relative gene expres-
sion compared to gapdh (mean ± SD) is shown. *, p < 0.05; **, p < 0.001.probably not be considered for topical delivery of siRNAs to any
mucosal surface, since they might also increase transmission of
other enveloped viruses. Although unmodified siRNAs can
apparently be taken up and induce silencing in the pulmonary
epithelium without the aid of a transfection reagent (Bitko
et al., 2005), we did not find that to be the case in the genital tract
of mice. It is possible that application of significantly higher
siRNA concentrations could knock down gene expression in
the tissue, but we did not evaluate this, since chol-siRNAs
provided an efficient and apparently nontoxic method for genital
tract delivery. However, our evaluation of toxicity was limited to
gross assessments of epithelial cell integrity and inflammatoryCeinfiltrates and induction of inflammatory cytokines. Although
mice treated with a 5-fold-higher dose of siRNA did not appear
to become sick, this dose did not afford any viral protection.
This may be because of dose-dependent off-target effects or
toxicity, which would need to be carefully evaluated for further
preclinical development.
Ivag administration of chol-siRNAs did not induce substantial
interferon or inflammatory responses. In contrast to two recent
studies that reported induction of high levels of inflammatory
chemokines IFNb, IFNg, and IL12 by some siRNA preparations
(Kleinman et al., 2008; Robbins et al., 2008), we found no indica-
tion that these cytokines were significantly induced followingll Host & Microbe 5, 84–94, January 22, 2009 ª2009 Elsevier Inc. 91
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addition, no survival advantage was observed in mice given
siRNAs targeting GFP compared with mice receiving no siRNAs.
Therefore, the protective effect is likely a direct consequence of
specific siRNA-mediated gene silencing.
HSV-2 infects epithelial cells and dorsal root ganglion neurons.
Our results support efficient chol-siRNA delivery to epithelial
cells, but this acute HSV-2 infection model does not address
whether neuronal processes that extend into the tissue are effec-
tively transduced. Topically applied siRNAs might be useful to
treat and prevent reactivation and sexual transmission of clini-
cally latent HSV-2 infection, which is not truly latent since chron-
ically infected women without clinical symptoms of active
disease are constantly shedding infectious virus (Wald, 2004).
An ideal drug would also prevent viral replication in the dorsal
root ganglion viral reservoir. Further studies are therefore needed
to examine siRNA transduction of these cells. We would also like
to apply the results of this study to developing a topical microbi-
cide to prevent HIV-1 infection, an urgent global public health
need given the failures of HIV vaccine development. Since HIV,
like HSV-2, is an enveloped virus, transfection lipid-mediated
delivery would likely be inadvisable. To prevent HIV transmis-
sion, we need to develop a way to transduce immune cells in
the genital tract responsible for HIV transmission, especially
Langerhans cells, macrophages, and T cells. Because these
cells are rare in the uninflamed genital tissue of mice maintained
under pathogen-free conditions, we do not yet know whether
chol-siRNAs will be suitable, but we are evaluating this.
This study confirms that nectin-1, a cell-adhesion molecule
that localizes at the adherans junctions of epithelial cells, is an
important HSV-2 receptor (Geraghty et al., 1998; Cocchi et al.,
1998; Shukla et al., 2000). In addition to nectin-1, herpesvirus
entry mediator (HVEM) has been reported as an efficient entry
receptor for HSV (Montgomery et al., 1996). However, in mice
genetically deleted for HVEM, little difference in HSV-2 ivag
infectivity was observed. By contrast, mice lacking nectin-1
exhibited reduced infection levels in the vaginal epithelium and
decreased viral spread to the nervous system. Death was
delayed in nectin-1 knockout mice, and approximately half the
mice succumbed to disease (Taylor et al., 2007). The superior
protection from HSV-2 infection afforded by nectin-1 knock-
down, where 80% of mice were protected, compared to
knockout mice could be due to differences in mouse or virus
strains or potentially to compensatory changes in expression
of members of the nectin and nectin-like family in knockout
animals. The correlation between nectin-1 expression at the
luminal surface in diestrus with susceptibility to HSV-2 infection
in mice further supports the importance of nectin-1 as a viral
receptor, as previously reported (Linehan et al., 2004). Of note,
nectin-1 is expressed at all stages of the menstrual cycle in
humans (Linehan et al., 2004).
Therapeutically knocking down a host gene can be deleterious
if the gene is required for normal cellular function. Because nec-
tin-1 localizes to adherens junctions, it might be required to
maintain the integrity of the epithelial barrier. However, we saw
no changes in histology of the epithelial layer by hematoxylin
and eosin staining. Nectin-1 has been identified as a gene
mutated in cleft lip or cleft palate syndrome. The incidence of
this mutation in some populations may be a result of selection92 Cell Host & Microbe 5, 84–94, January 22, 2009 ª2009 Elsevierdue to a survival advantage conferred by relative resistance to
HSV-1 and HSV-2 (Suzuki et al., 2000). However, whether this
mutation confers a protective effect is, as yet, undetermined.
Therefore, nectin-1 may be needed for development, but may
be a nonessential gene (and good microbicide target) after
that. However, the use of nectin-1 siRNAs might not be without
risk during pregnancy.
siRNAs targeting viral genes were effective over a limited time
frame, but siRNAs targeting a putative host receptor provided
more sustained protection against both in vitro and in vivo viral
challenge. We previously found that siRNAs targeting CCR5,
the host coreceptor for HIV, protected macrophages from HIV-
1 infection in vitro for weeks, whereas protection waned after
a few days when uninfected cells were transduced with HIV-1
gag siRNAs (Song et al., 2003). These data, together with the
observation in C. elegans that siRNAs are more stable when
a target mRNA is expressed (Plasterk, 2002), suggested that
siRNAs targeting host genes might persist longer and provide
more sustained protection than siRNAs targeting viral genes.
Although the outcome was as expected (namely, silencing nec-
tin-1 provided more durable protection than UL29 siRNAs), the
explanation was not what we expected. The half-lives of nec-
tin-1 and UL29 siRNAs in uninfected NIH 3T3 cells are in fact
comparable. Similarly, we did not find a difference in half-life of
GFP siRNAs in GFP-expressing and -nonexpressing HeLa cells
(data not shown). Therefore, the stability of an siRNA does not
appear to be affected by the expression of its target gene.
However, there was significantly more intracellular nectin-1
siRNA compared to UL29 siRNA at all time points. This may be
because the nectin-1 siRNA was more efficiently taken up into
RNA-induced silencing complexes (RISC) and available for
gene silencing. In fact, the level of intracellular nectin-1 siRNA
7 days after transfection was similar to the level of UL29 siRNA
on the first day after transfection. What this suggests is that
the difference in durable protection may not be due to targeting
a host receptor versus a viral gene, but rather to the use of amore
effective siRNA. Therefore, identifying more effective siRNAs
that are either more efficiently incorporated into RISC or more
active at directing target mRNA degradation might generate
not only siRNAs active at a lower dose, but those that last longer.
For this study and our previous study, we tested only a few siR-
NAs for each target gene; a systematic approach to identify host
or viral gene siRNAs active at pM concentrations in vitro would
be advisable for preclinical development. These could be
directed against either viral or host genes. Use of optimized
siRNA sequences or further chemical modification of siRNAs to
enhance stability in the genital tract might lower the siRNA




Six-week-old BALB/c mice (Taconic Farms) were injected subcutaneously
with 2 mg medroxyprogesterone acetate (Sicor) 1 week prior to siRNA treat-
ment or HSV-2 challenge. Mice were challenged ivag with 2 3 104
(2 LD50), 104, or 5 3 103 pfu HSV-2 strain 186. siRNA formulations were
administered ivag twice on consecutive days. The following siRNAs
were used: 1 nmol PS-modified siRNA without transfection reagent, 1 nmol
PS-modified siRNAs complexed with 2 ml Oligofectamine (Invitrogen), orInc.
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An siRNA-Based HSV-2 Microbicidechol-PS-siRNA (2 nmol unless otherwise specified) without transfection
reagent. Following HSV-2 challenge, disease progression was graded accord-
ing to a five-point scale: 0, no signs of infection (purple); 1, slight genital
erythema and edema (blue); 2, moderate genital inflammation (green); 3, puru-
lent genital lesions (yellow); 4, hind limb paralysis (orange); 5, death (red) (Mor-
rison et al., 1998). Vaginal tissue was dissected at the times indicated, fixed in
10% formalin (Sigma), paraffin embedded, cut into 8 mm sections, and stained
with hematoxylin and eosin. For RNA isolation, vaginal tissue was stored in
RNAlater (QIAGEN) prior to RNA extraction using RNeasy (QIAGEN).
Viruses and Transfection Assays
For in vitro transfection assays, replication-competent HSV-2 186Dkpn (the
TK-negative mutant) was used (Jones et al., 2000). Wild-type 186 syn+ HSV-
2 was used for in vivo experiments (Spang et al., 1983). Viruses were grown
and titered on Vero cells, as described (Gao and Knipe, 1989). An aliquot of
virus used for each mouse experiment was assayed by plaque assay to
confirm viral titer. For transfection assays, NIH 3T3 cells were plated (2 3
105 cells per well in 6-well plates in 1 ml of complete medium). The following
day, cells were transfected with 100 pmol siRNA complexed with TransIT-
siQUEST (Mirus), according to the manufacturer’s instructions. After 18 hr
incubation at 37C, complexes were removed and replaced with complete
medium. The transfection was repeated, as above, 6 hr later; the following
day, complexes were removed, and complete mediumwas added to the cells.
HSV-2 186Dkpn was added 6 hr later at an MOI of 1 and incubated for 1 hr at
37C, and themediumwas then replaced. Cells were harvested 24 hr later, and
viral titer was determined by plaque assay on Vero cells. Cells used in transfec-
tion experiments to determine siRNA half-life were transfected as described,
but were maintained in 1% FCS serum to minimize cell turnover.
siRNAs
Unmodified siRNAs (Dharmacon) were prepared according to the manufac-
turer’s instructions. PS-modified and chol-PS-modified siRNAs were
synthesized as described (Soutschek et al., 2004). The siRNA sequences
used were as follows:
HSV-2 UL29 (Palliser et al., 2006) (GenBank accession number
NC 001798; nt 60324–60342): sense, 50-CUUUCGCAAUCAAUUC
CAAdT*dT-30; antisense, 50-UUGGAAUUGAUUGCGAAAGdT*dT*chol-30
Nectin-1 sequence #1 (GenBank accession number NM 021424; nt 742–
760): sense, 50-CCUGCAUUGUCAACUAUCAdT*dT*chol-30; antisense,
50-UGAUAGUUGACAAUGCAGGdT*dT-30
Nectin-1 sequence #2 (GenBank accession number NM 021424; nt 1234–
1252): sense, 50-GCACCAAGAAGCACGUGUAdTdT-30; antisense, 50-UA
CACGUGCUUCUUGGUGCdTdT-30
SET (Fan et al., 2003) (GenBank accession number NM 003011; nt 34–52):
sense, 50-GGAGCUCAACUCCAACCACUU-30; antisense, 50-GUGGUU
GGAGUUGAGCUCCUU-30
GFP (Novina et al., 2002): sense, 50-GGCUACGUCCAGGAGCGCA
dT*dT*chol-30; antisense, 50-UGCGCUCCUGGACGUAGCCdT*dT-30
* designates substitution of a phosphodiester bond with a PS linkage; chol
indicates cholesterol conjugation. The cholesterol-conjugated sequences
were purified by high-performance liquid chromatography (HPLC) on
a reverse-phase column. RNA oligonucleotides were purified by anion-
exchange HPLC. Fractions containing full-length oligonucleotides were
pooled, desalted, and lyophilized and characterized by ES mass spectrometry
and capillary gel electrophoresis (Soutschek et al., 2004). Purity was in the
range of 90%. Unmodified siRNAs contained no PS linkages or cholesterol.
Quantitative RT-PCR
Total RNA (1 mg) was isolated from mouse vaginal tissue using the RNeasy
RNA isolation kit (QIAGEN) and reverse transcribed using Superscript III
(Invitrogen) and random hexamers (IDT), according to the manufacturer’s
instructions. Real-time PCR was performed on 0.2 ml of complementary
DNA using Platinum Taq polymerase (Invitrogen) and a Biorad iCycler. SYBR
Green (Molecular Probes) was used to detect PCR products. All reactions
were done in 25 ml in triplicate. Primers were:
Gapdh forward: 50-TTCACCACCATGGAGAAGGC-30












PCR parameters consisted of 5 min Taq activation at 95C followed by
40 cycles of 95C 3 20 s, 60C 3 30 s, and 69C 3 20 s. Standard curves
were generated, and relative amount of mRNA was normalized to Gapdh
mRNA. Specificity was verified bymelt curve analysis and agarose gel electro-
phoresis.
Tissue Sections and Microscopy
Nectin-1 expression in vaginal tissue was assayed using a protocol adapted
from Zhao et al., 2003. Briefly, frozen 8 mm sections were acetone fixed,
blocked in TNB buffer (NEN Life Sciences Products) containing 5% normal
donkey serum, and then blocked in avidin-biotin solution (Vector Laborato-
ries). Endogenous peroxidase activity was quenched with 1% H2O2. Slides
were incubated overnight at 4C with either polyclonal nectin-1 antibody
(Orbigen) or isotype-control IgG. Slides were washed and then incubated for
1 hr at room temperature with biotin goat anti-rabbit Ig (InnoGenex) followed
by incubation for 40 min at room temperature with steptavidin-HRP (InnoGe-
nex). The antigenic signal was amplified with tyramide amplification kit (Invitro-
gen), according to the manufacturer’s instructions. Slides were then washed
and mounted with Vectashield Mounting Medium containing the nuclear dye
DAPI (Vector Laboratories). For CD45 staining, frozen sections were fixed
and blocked, as above. Primary antibodies were anti-mouse CD45 antibody
or rat IgG2b isotype control (Pharmingen). Alexa Fluor 594 donkey anti-rat
IgG (Molecular Probes) was used as the secondary antibody. Following stain-
ing, sections were washed and mounted with Vectashield Mounting Medium,
as above. For hematoxylin-eosin staining, tissues were fixed in 10% formalin
followed by paraffin embedding. Images were acquired and analyzed using
Slidebook software (Intelligent Imaging) on a Zeiss Axiovert 200Mmicroscope.
RNA Extraction and Northern Blot Analysis
Total RNA was isolated using Trizol (Invitrogen). RNA samples (20 mg) were
resolved on 15% TBE-Urea acrylamide gels containing 20% formamide and
then either visualized with Stains-All (Sigma) or transferred onto Nytran-SPC
Nylon Membranes (Whatman) and UV-crosslinked. The membranes were pre-
hybridized at 42C in 7% SDS/0.2 M sodium phosphate buffer and hybridized
overnight at 42C with an a-32P dATP 30 end-labeled oligoprobe against the
siRNA antisense strand. The sequences of the DNA oligoprobes were:
siRNA nectin: 50-CCTGCATTGTCAACTATCA-30
siRNA UL29: 50-CTTTCGCAATCAATTCCAA-30
After washing twice at room temperature with 23 SSC/0.1% SDS, the
membranes were developed and bands quantified using a PhosphorImager
(Storm 860, GE Healthcare). Membranes were probed with an oligoprobe
against U6 as a loading control, which was used to normalize the intensity of
each band.
Statistical Analysis
The main outcome was overall survival (OS), defined as the time from treat-
ment to death. OS curves were obtained using the Kaplan-Meier method
(Kaplan and Meier, 1958) and compared by the log-rank test (Mantel, 1966).
We also tested the effect of treatment while adjusting for the effect of time
of viral challenge. The log-rank linear rank statistics were computed by pooling
over the strata defined by the time of the challenge, thus adjusting for the effect
of time of the challenge. All in vitro measurements were compared by two-
sample Student’s t test. The half-lives of the nectin-1 and UL29 siRNAs were
calculated after logarithmic transformation of the relative siRNA/U6 values
and measuring the slope of the linear regression versus time. All P values
reflect two-sided tests of significance.l Host & Microbe 5, 84–94, January 22, 2009 ª2009 Elsevier Inc. 93
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